Stock Events

Stock Events

InMed Pharmaceuticals 

$0.68
34
+$0.01+1.01% Today

Statistics

Day High
0.68
Day Low
0.65
52W High
3.87
52W Low
0.62
Volume
9,358
Avg. Volume
120,159
Mkt Cap
1.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q1 2024
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q4 2025
Next
-3.64
-2.49
-1.33
-0.18
Expected EPS
N/A
Actual EPS
N/A

Financials

-165.12%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
9.89MRevenue
-16.32MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap148.9M
Corbus Pharmaceuticals specializes in the development of drugs targeting inflammatory and fibrotic diseases, overlapping with InMed's therapeutic areas.
Aurora Cannabis
ACB
Mkt Cap280.01M
Aurora Cannabis is a major player in the cannabis industry, whose expansion into medical cannabis products puts it in direct competition with InMed's pharmaceutical cannabis products.
Tilray Brands
TLRY
Mkt Cap1.5B
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, potentially competing with InMed in the medical cannabis market.
Canopy Growth
CGC
Mkt Cap418.51M
Canopy Growth Corporation operates in the cannabis and hemp business, competing with InMed in the development of cannabinoid-based pharmaceuticals.
Curaleaf
CURLF
Mkt Cap2.16B
Curaleaf Holdings operates in the cannabis retail and medical cannabis oil production, competing with InMed in the cannabinoid-based product market.

About

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Eric A. Adams B.S. Chem., M.I.B.
Employees
13
Country
CA
ISIN
CA4576377002

Listings

F
DE
MWG.F
XNAS
US
INM
BOATS
BOATS
INM.BOATS

0 Comments

Share your thoughts

FAQ

What is InMed Pharmaceuticals stock price today?▼
The current price of INM is $0.68 USD — it has increased by +1.01% in the past 24 hours. Watch InMed Pharmaceuticals stock price performance more closely on the chart.
What is InMed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange InMed Pharmaceuticals stocks are traded under the ticker INM.
Is InMed Pharmaceuticals stock price growing?▼
INM stock has fallen by -0.59% compared to the previous week, the month change is a -17.43% fall, over the last year InMed Pharmaceuticals has showed a -67.37% decrease.
What is InMed Pharmaceuticals market cap?▼
Today InMed Pharmaceuticals has the market capitalization of 1.9M
When is the next InMed Pharmaceuticals earnings date?▼
InMed Pharmaceuticals is going to release the next earnings report on May 18, 2026.
What is InMed Pharmaceuticals revenue for the last year?▼
InMed Pharmaceuticals revenue for the last year amounts to 9.89M USD.
What is InMed Pharmaceuticals net income for the last year?▼
INM net income for the last year is -16.32M USD.
How many employees does InMed Pharmaceuticals have?▼
As of April 02, 2026, the company has 13 employees.
In which sector is InMed Pharmaceuticals located?▼
InMed Pharmaceuticals operates in the Health Care sector.
When did InMed Pharmaceuticals complete a stock split?▼
The last stock split for InMed Pharmaceuticals was on November 14, 2024 with a ratio of 1:20.
Where is InMed Pharmaceuticals headquartered?▼
InMed Pharmaceuticals is headquartered in Vancouver, CA.